European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Inotrem SA, Vandœuvre-lès-Nancy, France

Watch
Inotrem SA

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Inotrem SA

Identification

Sirul
Siren 791682172
Siret
Siret 79168217200030
EUID
FR5402.791682172

Address

9 de la Foret de Haye, 54500 Vandœuvre-lès-Nancy, France
Nancy, France

Corporate purpose

72.19
Other research and experimental development on natural sciences and engineering

Research and development of drugs, diagnostic solutions and processes for the treatment and diagnosis of inflammatory and/or infectious diseases. And generally all financial, commercial, industrial, real estate and movable transactions that may be related, directly or indirectly, to the above-specified objects or to any other related or complementary object

History

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
2Chair of the board
1Director-General
2Director
1Director
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

19 Feb 2026
Corporate Purpose
18 Dec 2025
Ini­ti­a­tion · Corporate Purpose
16 Aug 2025 also 17/12/2024, 10/10/2023, 06/11/2022, 10/10/2021, 09/03/2021, 09/10/2019, 13/07/2018, 11/01/2018, 06/10/2016, 22/07/2015
Bulletin officiel des annonces civiles et commerciales
14 Aug 2025
Director (3) · Director: Bpifrance Investissement, Morningside Venture Investments Ltd., Sofinnova Partners · Capital: €938,213
14 Aug 2025
Capital: €1,526,094
11 Aug 2024
Director (6) · Chair (1) · Deputy Managing Director (1) · Director: Andera Partners, Morningside Venture Investments Ltd., Sofinnova Partners · Auditor: Deloitte & Associes · Corporate Purpose
24 May 2024
Patent: Compositions with Trem-1 inhibitors and uses thereof
10 Jan 2024
Patent: Procedures and kits for predicting the risk of a cardiovascular event
28 Feb 2023
Director (6) · Chair (1) · Deputy Managing Director (1) · Director: Andera Partners, Morningside Venture Investments Ltd., Sofinnova Partners · Auditor: Deloitte & Associes · Corporate Purpose
21 Feb 2023
Director: Andera Partners SCA
23 Sept 2022
Director (9) · Chair of the board (1) · Director-General (1) · Director: Andera Partners, Morningside Venture Investments Ltd., Sofinnova Partners · Auditor: Deloitte et Associes · Corporate Purpose
23 Sept 2022
Director (6) · Chair of the board (1) · Deputy Managing Director (1) · Auditor: Deloitte & Associes · Corporate Purpose
21 Sept 2022
Director (2) · Director: Sofinnova Partners SAS · Auditor: Deloitte & Associes SAS
7 Jul 2022
Director (1)
5 Jul 2022
Director (6) · Chair of the board (1) · Director-General (1) · Director: Andera Partners, Morningside Venture Investments Ltd., Sofinnova Partners · Auditor: Deloitte et Associes
30 Jun 2022
Director (1)
2 Jun 2022
Patent: Anti-Trem-1 antibody
25 May 2022
Reg­is­tra­tion: 25/05/2022 · Address · Legal form: SA à conseil d'administration (s.a.i.) · Name: INOTREM · Segment clas­si­fi­ca­tion
7 Oct 2021
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
23 Sept 2021
Capital: €911,956 · Corporate Purpose
10 Sept 2021
Director-General (1) · Director (2) · Director: Andera Partners SCA, Morningside Venture Investments Ltd., Sofinnova Partners SCA · Auditor: Deloitte et Associes SA
18 Aug 2021
Director (1)
30 Jun 2021
Director (4) · Chair (1) · Deputy Managing Director (1) · Director: Andera Partners, Morningside Venture Investments Ltd., Sofinnova Partners · Auditor: Deloitte et Associes · Corporate Purpose
28 Jun 2021
Director-General (1) · Director (3) · No longer President (1) · No longer Director-General (1)
7 Jun 2021
Patent: Soluble Trem-1 as a marker of severity or complications for a person with coronavirus infection
7 Jun 2021
Patent: Trem-1 inhibitor for use IN the treatment of a person with coronavirus infection
19 Mar 2021
Chair (1) · Director (3) · Deputy Managing Director (1) · Director: Andera Partners, Morningside Venture Investments Ltd., Sofinnova Partners · Auditor: Deloitte et Associes · Corporate Purpose
17 Mar 2021
No longer Auditor: Beas Sàrl
5 Jun 2020
Patent: Soluble Trem-1 as a marker of severity or complications in a person suffering from a coronavirus infection
5 Jun 2020
Patent: Trem-1 Inhibitor for USE in the Treatment of a Subject Suffering From a Coronavirus Infection
10 May 2020
Capital: €701,818
29 Jan 2020
Capital: €665,674
9 Oct 2019
Chair (1) · Director (3) · Deputy Managing Director (1) · Director: Andera Partners (SCA), Morningside Venture Investments Ltd …
4 Oct 2019
Director: Morningside Venture Investments Ltd
2 Oct 2019
Capital: €665,574
27 Sept 2019
Patent: Use of soluble TREM 1 sets for identifying persons with susceptibility to an anti-inflammatory therapy
27 Sept 2019
Patent: Nangibotide for the treatment of sepsis shock
28 Sept 2018
Patent: Use of soluble Trem 1 mirrors to identify individuals susceptible to anti-inflammatory therapy
27 Jul 2018
Chair of the board (1) · Director (2) · Deputy Managing Director (1) · Director: Andera Partners (SCA), Sofinnova Partners (SCA) · Auditor: Beas (Sàrl), Deloitte et Associes (sa)
18 Jul 2018
No longer Director (2) · Director: Andera Partners SCA, Sofinnova Partners SCA
28 Jan 2018
Capital: €369,019
24 Nov 2016
Transfer of head office, transfer of principal place of business
22 Nov 2016
Director-General (1) · Director (3) · Auditor: Beas Sàrl, Deloitte et Associes SA
17 Jun 2016
Address
11 Apr 2014
Chair of the board (1) · Director (2) · Deputy Managing Director (1) · Auditor: Beas (Sàrl), Deloitte et Associes (sa) · Capital: €156,897
25 Feb 2014
Legal form: SA à conseil d'administration (s.a.i.)
31 Jan 2014
Patent: Methods and Kits for Predicting the Risk of Having a Cardiovascular Disease or Event
13 Aug 2013 as Inotrem SAS
Director-General (1) · President (1)
22 Mar 2013 as Inotrem SAS
Reg­is­tra­tion: 08/03/2013 · President (1) · Capital: €40,000 · Corporate Purpose
26 Feb 2013 as Inotrem SAS
Reg­is­tra­tion: 26/02/2013 · Address · Legal form: SAS, société par actions simplifiée · Name: INOTREM · Segment clas­si­fi­ca­tion
There are no publications matching your search.

Mentions

29 Sept 2026 in Rne
Reg­is­tra­tion: 26/02/2013 · DG: S. Z. · Chair: L. B., Th. H. · Director: E. P. · Director: Andera Partners SCA, Bpifrance Investissement SAS · Auditor: Deloitte & Associes SAS · Capital: €938,213
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.